Biomarin Pharmaceutical (BMRN) Share Price Rose While Argentiere Capital Ag Raised Stake; Southeast Asset Advisors Decreased Its Holding in Bio Techne (TECH) as Share Price Rose

August 12, 2018 - By Lisa Delgado

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo

Southeast Asset Advisors Inc decreased its stake in Bio Techne Corp (TECH) by 46% based on its latest 2018Q1 regulatory filing with the SEC. Southeast Asset Advisors Inc sold 4,099 shares as the company’s stock rose 4.37% while stock markets declined. The institutional investor held 4,812 shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $727,000, down from 8,911 at the end of the previous reported quarter. Southeast Asset Advisors Inc who had been investing in Bio Techne Corp for a number of months, seems to be less bullish one the $6.71 billion market cap company. The stock increased 0.22% or $0.4 during the last trading session, reaching $178.68. About 147,611 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 33.83% since August 12, 2017 and is uptrending. It has outperformed by 21.26% the S&P500. Some Historical TECH News: 02/05/2018 – Bio-Techne 3Q Adj EPS $1.21; 30/05/2018 – Bio-Techne Closes Above 50-Day Moving Average: Technicals; 02/05/2018 – Bio-Techne Declares Dividend; 22/04/2018 – DJ Bio-Techne Corporation, Inst Holders, 1Q 2018 (TECH); 10/04/2018 – Bio-Techne at Deutsche Bank Health Care Conference May 8; 07/05/2018 – Bio-Techne at Deutsche Bank Health Care Conference Tomorrow; 14/03/2018 – Bio-Techne Launches MimEX™ Gl, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract; 14/03/2018 Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract

Argentiere Capital Ag increased its stake in Biomarin Pharmaceutical Inc (BMRN) by 40% based on its latest 2018Q1 regulatory filing with the SEC. Argentiere Capital Ag bought 20,000 shares as the company’s stock rose 10.05% while stock markets declined. The hedge fund held 70,000 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $5.68M, up from 50,000 at the end of the previous reported quarter. Argentiere Capital Ag who had been investing in Biomarin Pharmaceutical Inc for a number of months, seems to be bullish on the $18.02 billion market cap company. The stock decreased 0.56% or $0.57 during the last trading session, reaching $101.46. About 600,593 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.91% since August 12, 2017 and is uptrending. It has underperformed by 6.66% the S&P500. Some Historical BMRN News: 21/03/2018 – BioMarin Closes Above 50-Day Moving Average: Technicals; 25/04/2018 – BioMarin Pharmaceutical 1Q Loss/Shr 26c; 22/05/2018 – BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress; 25/04/2018 – BIOMARIN PHARMACEUTICAL INC – AS OF MARCH 31, 2018, BIOMARIN HAD CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALING ABOUT $1.7 BLN; 24/05/2018 – BioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease; 25/04/2018 – BIOMARIN STILL SEES FY LOSS $115M TO $165M; 24/04/2018 – New England Journal of Medicine Published Open-label Study Showing Brineura┬« (cerliponase alfa) Reduced the Rate of Clinical D; 24/05/2018 – FDA OKS BIOMARIN’S PALYNZIQ FOR GENETIC DISEASE PHENYLKETONURIA; 25/04/2018 – BioMarin Pharmaceutical 1Q Rev $373.4M; 24/05/2018 – BioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (P

Argentiere Capital Ag, which manages about $464.87M and $234.45 million US Long portfolio, decreased its stake in Jpmorgan Chase & Co (NYSE:JPM) by 16,220 shares to 64,080 shares, valued at $7.05M in 2018Q1, according to the filing. It also reduced its holding in Western Digital Corp (NASDAQ:WDC) by 5,000 shares in the quarter, leaving it with 10,000 shares, and cut its stake in Monsanto Co New (NYSE:MON).

Investors sentiment decreased to 0.96 in Q1 2018. Its down 0.25, from 1.21 in 2017Q4. It is negative, as 38 investors sold BMRN shares while 124 reduced holdings. 36 funds opened positions while 119 raised stakes. 174.46 million shares or 1.43% more from 172.01 million shares in 2017Q4 were reported. Pdt Prns Ltd Llc reported 1% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Gam Ag has invested 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Nelson Van Denburg And Campbell Wealth Grp Limited Com owns 1,094 shares or 0.02% of their US portfolio. Jgp Glob Gestao De Recursos Ltda, Brazil-based fund reported 18,506 shares. Parametric Port Assoc Limited Liability Co owns 0.02% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 201,023 shares. Kbc Gp Nv holds 0.21% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 274,398 shares. Ls Advisors Limited Liability Corp reported 1,451 shares stake. Interest has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 17,089 shares. Paloma Prtnrs Management owns 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 10,438 shares. Torray Ltd Liability has 2.1% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 75,000 are owned by Eventide Asset Mngmt Llc. Hudson Bay Capital Mngmt Lp has 0.24% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Moreover, State Street has 0.03% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Comml Bank Of Mellon Corporation invested 0.03% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 88,058 were accumulated by Pub Employees Retirement Systems Of Ohio.

Among 28 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. BioMarin Pharmaceutical had 106 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Tuesday, February 27. The firm has “Outperform” rating given on Monday, August 6 by Wedbush. The company was maintained on Wednesday, January 24 by JP Morgan. On Tuesday, February 23 the stock rating was maintained by Oppenheimer with “Perform”. The rating was initiated by Goldman Sachs on Wednesday, November 18 with “Buy”. The rating was downgraded by PiperJaffray on Monday, November 7 to “Neutral”. Cowen & Co maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Wednesday, October 18. Cowen & Co has “Buy” rating and $150.0 target. On Wednesday, December 20 the stock rating was maintained by Wedbush with “Buy”. Morgan Stanley maintained the stock with “Overweight” rating in Friday, February 23 report. The rating was upgraded by Stifel Nicolaus on Tuesday, February 16 to “Buy”.

Since February 15, 2018, it had 0 buys, and 29 sales for $25.24 million activity. Shares for $166,379 were sold by Davis George Eric on Monday, March 5. $1.25 million worth of stock was sold by BIENAIME JEAN JACQUES on Friday, March 16. The insider SPIEGELMAN DANIEL K sold 11,059 shares worth $908,497. 3,145 shares were sold by Mueller Brian, worth $312,928. FUCHS HENRY J also sold $801,200 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. On Tuesday, April 17 LAWLIS V BRYAN sold $318,750 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 3,750 shares.

More important recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018, also Seekingalpha.com published article titled: “BioMarin: Gene Therapy Pipeline Driving Valuation Upside”, Seekingalpha.com published: “Premarket analyst action – healthcare” on August 07, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was released by: Seekingalpha.com and their article: “Spark Therapeutics down 25% premarket on SPK-8011 data” with publication date: August 07, 2018.

Southeast Asset Advisors Inc, which manages about $1.76B and $337.57M US Long portfolio, upped its stake in Ishares Tr (IJR) by 5,066 shares to 14,238 shares, valued at $1.10 million in 2018Q1, according to the filing. It also increased its holding in Schein Henry Inc (NASDAQ:HSIC) by 10,280 shares in the quarter, for a total of 27,030 shares, and has risen its stake in Blackbaud Inc (NASDAQ:BLKB).

Among 10 analysts covering BIO-TECHNE Corp (NASDAQ:TECH), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. BIO-TECHNE Corp had 28 analyst reports since August 18, 2015 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Thursday, February 9. Janney Capital downgraded the stock to “Neutral” rating in Monday, March 27 report. The stock has “Hold” rating by Wells Fargo on Thursday, July 13. Deutsche Bank maintained Bio-Techne Corporation (NASDAQ:TECH) on Thursday, March 1 with “Buy” rating. Deutsche Bank downgraded the shares of TECH in report on Wednesday, June 27 to “Hold” rating. On Tuesday, September 1 the stock rating was upgraded by Zacks to “Sell”. Janney Capital upgraded the stock to “Buy” rating in Tuesday, May 3 report. The company was reinitiated on Thursday, November 10 by Leerink Swann. On Thursday, October 29 the stock rating was downgraded by Stephens to “Equal-Weight”. The rating was maintained by Leerink Swann on Tuesday, December 5 with “Buy”.

Since February 13, 2018, it had 0 insider purchases, and 2 selling transactions for $1.44 million activity. Shares for $680,303 were sold by Dinarello Charles A on Tuesday, February 13. The insider Kummeth Charles R. sold 8,000 shares worth $1.28M.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts